Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RQC for Prevention of Alzheimer's Disease and Retinal Amyloid-β
NCT06470061Phase 2Not yet recruiting
- Sponsor
- Zaparackas and Knepper
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of resveratrol, quercetin and curcumin in Alzheimer's disease (AD), sponsored by Zaparackas and Knepper. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
resveratrolquercetincurcumin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06470061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470061.